Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately USD 106.3 million, a 287.2% year‑on‑year increase, and a net profit of approximately USD 35.54 million versus a net loss of USD 19.22 million in the same period last year — marking a decisive turnaround to profitability. With cash and investment portfolio of USD 584.8 million at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset Rentosertib entering a large‑scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).

Financial Highlights – 1H 2026

*Prior‑period figures implied by reported growth rates.

Revenue Drivers & Business Development

• BD Deal Engine: Drug discovery and pipeline development revenue surged to USD 103.1 million, up over 300% year on year, driven primarily by substantial upfront payments from a series of key business development (BD) deals reached during the period, alongside continued milestone payments from existing collaborations
• Deal Flow: As of the latest practicable date, the total value of transactions announced by Insilico Medicine in 2026 amounted to approximately USD 7.3 billion
• Second Growth Engine: Software solutions revenue grew steadily to USD 2.697 million, indicating that the MMAI Gym model training and evaluation ecosystem — under construction since 2026 — is gradually emerging as the company’s second growth pillar

AI‑Driven R&D Productivity & Pipeline Progress

• Preclinical Candidates: Since the beginning of 2026, Insilico has announced the nomination of nine preclinical candidates (PCCs), including ISM0676 (oral small‑molecule GIPR antagonist) and ISM5059 (peripherally restricted NLRP3 inhibitor), among others
• Clinical Momentum: Eight clinical advancements achieved across the pipeline in the same period
• Lead Asset – Rentosertib:
  • Initiated a large‑scale Phase 3 clinical trial in China for idiopathic pulmonary fibrosis (IPF)
  • An inhaled formulation of Rentosertib has also received clinical trial approval in China
• Generative AI Advantage: The company continues to leverage generative AI to improve R&D efficiency, shorten development cycles, and reduce R&D costs

Market Impact & Outlook

• Profitability Inflection: The swing from a USD 19.22 million loss to a USD 35.54 million profit marks a landmark validation of Insilico’s AI‑driven business model — rare among biotechs at this stage and potentially re‑rating for the stock.
• Deal‑Funded Growth: With ~USD 7.3 billion in announced 2026 transaction value, the company’s BD pipeline provides durable visibility on upfronts and milestones, de‑risking near‑term financial performance beyond 1H.
• Rentosertib as Flagship Catalyst: The large‑scale Phase 3 launch in IPF — a disease with severe unmet need and limited approved therapies — positions Rentosertib as the pivotal value driver, with the inhaled formulation adding differentiated delivery optionality.
• Watch Items: Phase 3 enrollment and interim readouts for Rentosertib, conversion of announced deals into executed agreements and milestone payments, progression of the nine newly nominated PCCs, and scaling of the MMAI Gym software ecosystem.

Forward‑Looking Statements – This brief is for informational purposes only and does not constitute investment advice. Interim results are unaudited; statements regarding pipeline development, BD transactions, and future financial performance are forward‑looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements and filings from Insilico Medicine for authoritative details.-Fineline Info & Tech